DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Makes New Investment in Encompass Health Co. (NYSE:EHC)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new position in Encompass Health Co. (NYSE:EHC - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 118,207 shares of the company's stock, valued at approximately $10,916,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main owned approximately 0.12% of Encompass Health at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. MassMutual Private Wealth & Trust FSB grew its stake in Encompass Health by 87.8% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company's stock valued at $27,000 after acquiring an additional 137 shares in the last quarter. Colonial Trust Co SC purchased a new stake in shares of Encompass Health during the 4th quarter worth about $29,000. Transce3nd LLC purchased a new stake in shares of Encompass Health during the 4th quarter worth about $40,000. CBIZ Investment Advisory Services LLC raised its stake in shares of Encompass Health by 38.7% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company's stock worth $42,000 after purchasing an additional 127 shares in the last quarter. Finally, Tompkins Financial Corp purchased a new stake in shares of Encompass Health during the 4th quarter worth about $46,000. Hedge funds and other institutional investors own 97.25% of the company's stock.

Encompass Health Stock Performance

Shares of EHC stock traded up $0.05 during trading on Thursday, reaching $119.32. The company had a trading volume of 413,032 shares, compared to its average volume of 689,304. The firm's 50 day simple moving average is $104.54 and its two-hundred day simple moving average is $100.41. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.05 and a quick ratio of 1.04. Encompass Health Co. has a one year low of $82.74 and a one year high of $120.11. The company has a market capitalization of $12.03 billion, a PE ratio of 26.77, a PEG ratio of 2.31 and a beta of 0.91.

Encompass Health (NYSE:EHC - Get Free Report) last released its earnings results on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.19 by $0.18. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The company's revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the firm posted $1.12 EPS. Sell-side analysts forecast that Encompass Health Co. will post 4.8 earnings per share for the current year.

Encompass Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Tuesday, July 1st will be issued a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date of this dividend is Tuesday, July 1st. Encompass Health's dividend payout ratio (DPR) is currently 14.05%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on EHC shares. UBS Group raised their price target on Encompass Health from $117.00 to $130.00 and gave the stock a "buy" rating in a research note on Monday, April 28th. Barclays raised their price target on Encompass Health from $118.00 to $129.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. KeyCorp raised their price target on Encompass Health from $120.00 to $122.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. William Blair reaffirmed an "outperform" rating on shares of Encompass Health in a research note on Friday, February 7th. Finally, Truist Financial reaffirmed a "buy" rating and set a $135.00 price target (up from $116.00) on shares of Encompass Health in a research note on Monday, April 28th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Encompass Health currently has a consensus rating of "Buy" and an average target price of $120.86.

Insider Buying and Selling at Encompass Health

In other Encompass Health news, insider Elissa Joy Charbonneau sold 4,279 shares of Encompass Health stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $116.61, for a total value of $498,974.19. Following the completion of the transaction, the insider now owns 11,958 shares in the company, valued at approximately $1,394,422.38. The trade was a 26.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP John Patrick Darby sold 10,000 shares of the business's stock in a transaction on Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total value of $1,147,900.00. Following the sale, the executive vice president now owns 79,710 shares of the company's stock, valued at approximately $9,149,910.90. The trade was a 11.15% decrease in their position. The disclosure for this sale can be found here. Insiders own 2.00% of the company's stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.